The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EKTAY | +6.09% | -45.89% | -11.56% | +204% |
| S&P | +12.93% | +85.68% | +13.18% | +674% |
Elekta AB operates as a medical technology company. It engages in the provision of clinical solutions for the treatment of cancers and brain disorders. The firm's products and solutions include radiotherapy, stereotactic radiosurgery, oncology informatics, brachytheraphy, neurosurgery, and particle therapy. It operates through the following geographical segments: North and South America, Europe, Middle East and Africa and Asia Pacific. The company was founded by Lars Leksell and Laurent Leksell in 1972 and is headquartered in Stockholm, Sweden.
No news articles found for Elekta Ab (publ).
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $430.31M | 2.8% |
| Gross Profit | $162.61M | 9.3% |
| Gross Margin | 37.79% | 2.2% |
| Market Cap | $1.83B | -16.2% |
| Market Cap / Employee | $0.40M | 0.0% |
| Employees | 4.6K | -1.8% |
| Net Income | $24.21M | 16.8% |
| EBITDA | $56.67M | -0.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $271.37M | -13.4% |
| Accounts Receivable | $350.17M | -6.7% |
| Inventory | 325.1 | 2.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $685.38M | 0.0% |
| Short Term Debt | $115.46M | -36.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 0.95% | -2.3% |
| Return On Invested Capital | 6.86% | -1.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $64.46M | 76.1% |
| Operating Free Cash Flow | $66.68M | 55.2% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 23.33 | 95.67 | 76.17 | 67.98 | 183.81% |
| Price to Book | 2.30 | 1.99 | 2.03 | 2.05 | -10.14% |
| Price to Sales | 1.35 | 1.14 | 1.09 | 1.12 | -17.23% |
| Price to Tangible Book Value | -7.02 | -6.59 | -5.53 | -5.91 | -33.42% |
| Price to Free Cash Flow TTM | 19.82 | 13.71 | 10.41 | 9.52 | -55.77% |
| Enterprise Value to EBITDA | 42.75 | 22.65 | 63.67 | 43.89 | -11.88% |
| Free Cash Flow Yield | 5.0% | 7.3% | 9.6% | 10.5% | 126.08% |
| Return on Equity | 9.9% | 2.2% | 2.6% | 3.1% | -69.48% |
| Total Debt | $801.31M | $784.56M | $792.95M | $800.84M | -7.76% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
